10 20 30 40 50 60 70 80 3HO0 - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER TRANSCRIPTION 01-JUN-09 3HO0
TITLE CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW TITLE 2 ARYLOXY-3PHENYLPROPANOIC ACID
COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LIGAND BINDING DOMAIN (LBD), UNP RESIDUES 223- COMPND 5 504; COMPND 6 SYNONYM: PPAR-GAMMA, NUCLEAR RECEPTOR SUBFAMILY 1 GROUP C COMPND 7 MEMBER 3; COMPND 8 ENGINEERED: YES
SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PPARG, NR1C3; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET28A
KEYWDS BUNDLE OF ALPHA-HELICES, SMALL FOUR-STRANDED BETA-SHEET, KEYWDS 2 TRANSCRIPTION, ACTIVATOR, ALTERNATIVE SPLICING, DIABETES KEYWDS 3 MELLITUS, DISEASE MUTATION, DNA-BINDING, METAL-BINDING, KEYWDS 4 NUCLEUS, OBESITY, PHOSPHOPROTEIN, POLYMORPHISM, RECEPTOR, KEYWDS 5 TRANSCRIPTION REGULATION, ZINC, ZINC-FINGER
EXPDTA X-RAY DIFFRACTION
AUTHOR G.POCHETTI,R.MONTANARI,F.MAZZA,F.LOIODICE,G.FRACCHIOLLA, AUTHOR 2 A.LAGHEZZA,A.LAVECCHIA,E.NOVELLINO
REVDAT 1 27-OCT-09 3HO0 0
JRNL AUTH G.FRACCHIOLLA,A.LAGHEZZA,L.PIEMONTESE,P.TORTORELLA, JRNL AUTH 2 F.MAZZA,R.MONTANARI,G.POCHETTI,A.LAVECCHIA, JRNL AUTH 3 E.NOVELLINO,S.PIERNO,D.CONTE CAMERINO,F.LOIODICE JRNL TITL NEW 2-ARYLOXY-3-PHENYL-PROPANOIC ACIDS AS JRNL TITL 2 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS JRNL TITL 3 ALPHA/GAMMA DUAL AGONISTS WITH IMPROVED POTENCY AND JRNL TITL 4 REDUCED ADVERSE EFFECTS ON SKELETAL MUSCLE FUNCTION JRNL REF J.MED.CHEM. V. 52 6382 2009 JRNL REFN ISSN 0022-2623 JRNL PMID 19775169 JRNL DOI 10.1021/JM900941B
REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH R.MONTANARI,F.SACCOCCIA,E.SCOTTI,M.CRESTANI, REMARK 1 AUTH 2 C.GODIO,F.GILARDI,F.LOIODICE,G.FRACCHIOLLA, REMARK 1 AUTH 3 A.LAGHEZZA,P.TORTORELLA,A.LAVECCHIA,E.NOVELLINO, REMARK 1 AUTH 4 F.MAZZA,M.ASCHI,G.POCHETTI REMARK 1 TITL CRYSTAL STRUCTURE OF THE PEROXISOME REMARK 1 TITL 2 PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARGAMMA) REMARK 1 TITL 3 LIGAND BINDING DOMAIN COMPLEXED WITH A NOVEL REMARK 1 TITL 4 PARTIAL AGONIST: A NEW REGION OF THE HYDROPHOBIC REMARK 1 TITL 5 POCKET COULD BE EXPLOITED FOR DRUG DESIGN REMARK 1 REF J.MED.CHEM. V. 51 7768 2008 REMARK 1 REFN ISSN 0022-2623 REMARK 1 PMID 19053776 REMARK 1 DOI 10.1021/JM800733H
REMARK 2 REMARK 2 RESOLUTION. 2.60 ANGSTROMS.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES, PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.60 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 NUMBER OF REFLECTIONS : 20317 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.258 REMARK 3 FREE R VALUE : 0.328 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 985 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4330 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 26 REMARK 3 SOLVENT ATOMS : 106 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 68.40 REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.009 REMARK 3 BOND ANGLES (DEGREES) : 1.30 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : ISOTROPIC REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4 REMARK 4 3HO0 COMPLIES WITH FORMAT V. 3.20, 01-DEC-08
REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 03-JUN-09. REMARK 100 THE RCSB ID CODE IS RCSB053369.
REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 09-MAY-08 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.933 REMARK 200 MONOCHROMATOR : DIAMOND (111), GE(220) REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 20618 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.600 REMARK 200 RESOLUTION RANGE LOW (A) : 25.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 5.0 REMARK 200 DATA REDUNDANCY : 3.800 REMARK 200 R MERGE (I) : 0.08300 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 4.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.60 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.74 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.0 REMARK 200 DATA REDUNDANCY IN SHELL : 3.90 REMARK 200 R MERGE FOR SHELL (I) : 0.34900 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 1.900 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: PDB ENTRY 3B3K REMARK 200 REMARK 200 REMARK: NULL
REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 53.03 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.62 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.8M NACITRATE, 0.15M TRIS, PH8.0, REMARK 280 VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K
REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 46.89500 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 30.72950 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 46.89500 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 30.72950 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL
REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA.
REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2010 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 26730 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -10.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 2 1.000000 0.000000 0.000000 -46.89500 REMARK 350 BIOMT2 2 0.000000 1.000000 0.000000 30.72950 REMARK 350 BIOMT3 2 0.000000 0.000000 1.000000 0.00000
REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 191 REMARK 465 SER A 192 REMARK 465 HIS A 193 REMARK 465 MET A 194 REMARK 465 ALA A 195 REMARK 465 GLU A 196 REMARK 465 ILE A 197 REMARK 465 SER A 198 REMARK 465 SER A 199 REMARK 465 ASP A 200 REMARK 465 ILE A 201 REMARK 465 ASP A 202 REMARK 465 GLN A 203 REMARK 465 LEU A 204 REMARK 465 ASN A 205 REMARK 465 PRO A 206 REMARK 465 GLY B 191 REMARK 465 SER B 192 REMARK 465 HIS B 193 REMARK 465 MET B 194 REMARK 465 ALA B 195 REMARK 465 GLU B 196 REMARK 465 ILE B 197 REMARK 465 SER B 198 REMARK 465 SER B 199 REMARK 465 ASP B 200 REMARK 465 ILE B 201 REMARK 465 ASP B 202 REMARK 465 GLN B 203 REMARK 465 LEU B 204 REMARK 465 ASN B 205 REMARK 465 PRO B 206
REMARK 475 REMARK 475 ZERO OCCUPANCY RESIDUES REMARK 475 THE FOLLOWING RESIDUES WERE MODELED WITH ZERO OCCUPANCY. REMARK 475 THE LOCATION AND PROPERTIES OF THESE RESIDUES MAY NOT REMARK 475 BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 475 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE) REMARK 475 M RES C SSEQI REMARK 475 LYS A 263 REMARK 475 PHE A 264 REMARK 475 LYS A 265 REMARK 475 HIS A 266 REMARK 475 ILE A 267 REMARK 475 THR A 268 REMARK 475 PRO A 269 REMARK 475 LEU A 270 REMARK 475 GLN A 271 REMARK 475 GLU A 272 REMARK 475 GLN A 273 REMARK 475 SER A 274 REMARK 475 ASP A 475 REMARK 475 LEU A 476 REMARK 475 GLU B 259 REMARK 475 ASP B 260 REMARK 475 ILE B 267 REMARK 475 THR B 268 REMARK 475 PRO B 269 REMARK 475 LEU B 270 REMARK 475 GLN B 271 REMARK 475 GLU B 272 REMARK 475 GLN B 273 REMARK 475 SER B 274 REMARK 475 ARG B 357 REMARK 475 LYS B 474 REMARK 475 ASP B 475 REMARK 475 LEU B 476
REMARK 480 REMARK 480 ZERO OCCUPANCY ATOM REMARK 480 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 480 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 480 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 480 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 480 M RES C SSEQI ATOMS REMARK 480 GLU B 207 CB CG CD OE1 OE2 REMARK 480 LYS B 358 CB CG CD CE NZ
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 244 91.33 -170.94 REMARK 500 ASP A 251 -178.58 -175.50 REMARK 500 ASP A 260 -91.07 -50.71 REMARK 500 PRO A 269 -151.90 -70.97 REMARK 500 SER A 274 78.42 -158.91 REMARK 500 LYS A 275 95.32 55.44 REMARK 500 LYS A 358 -60.79 -4.35 REMARK 500 PRO A 359 -73.57 -80.30 REMARK 500 PHE A 360 -30.95 -34.34 REMARK 500 SER A 394 -87.87 -67.11 REMARK 500 VAL A 403 -46.63 -165.68 REMARK 500 LYS A 474 -158.32 -154.40 REMARK 500 PRO B 227 -74.23 -60.74 REMARK 500 LEU B 237 -157.27 -58.32 REMARK 500 LYS B 240 -90.26 -78.70 REMARK 500 THR B 241 44.02 35.38 REMARK 500 ASP B 243 -18.34 -146.05 REMARK 500 LYS B 244 64.09 -155.87 REMARK 500 MET B 257 37.89 -69.59 REMARK 500 LYS B 263 38.32 -93.36 REMARK 500 HIS B 266 -72.56 -174.86 REMARK 500 GLU B 272 75.21 -164.62 REMARK 500 LYS B 275 103.59 63.76 REMARK 500 SER B 342 74.80 43.89 REMARK 500 GLU B 343 14.11 51.53 REMARK 500 ARG B 357 162.09 -45.29 REMARK 500 LEU B 393 48.19 -83.24 REMARK 500 SER B 394 -111.73 -61.49 REMARK 500 SER B 428 77.65 -105.73 REMARK 500 GLN B 451 -77.16 -62.78 REMARK 500 LYS B 457 10.30 -67.41 REMARK 500 THR B 459 -50.33 -139.34 REMARK 500 THR B 461 -97.44 -144.72 REMARK 500 ASP B 462 98.14 -46.25 REMARK 500 SER B 464 13.63 -69.42 REMARK 500 LYS B 474 -89.41 -60.79 REMARK 500 ASP B 475 -52.37 -137.01 REMARK 500 REMARK 500 REMARK: NULL
REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE DKD A 1
REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3B3K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PPARGAMMA-LBD COMPLEXED WITH A CHIRAL REMARK 900 CLOFIBRIC ACID ANALOGUE REMARK 900 RELATED ID: 3HOD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW REMARK 900 ARYLOXY-3PHENYLPROPANOIC ACID
DBREF 3HO0 A 195 476 UNP P37231 PPARG_HUMAN 223 504 DBREF 3HO0 B 195 476 UNP P37231 PPARG_HUMAN 223 504
SEQADV 3HO0 GLY A 191 UNP P37231 EXPRESSION TAG SEQADV 3HO0 SER A 192 UNP P37231 EXPRESSION TAG SEQADV 3HO0 HIS A 193 UNP P37231 EXPRESSION TAG SEQADV 3HO0 MET A 194 UNP P37231 EXPRESSION TAG SEQADV 3HO0 GLY B 191 UNP P37231 EXPRESSION TAG SEQADV 3HO0 SER B 192 UNP P37231 EXPRESSION TAG SEQADV 3HO0 HIS B 193 UNP P37231 EXPRESSION TAG SEQADV 3HO0 MET B 194 UNP P37231 EXPRESSION TAG
SEQRES 1 A 286 GLY SER HIS MET ALA GLU ILE SER SER ASP ILE ASP GLN SEQRES 2 A 286 LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU ALA LYS SEQRES 3 A 286 HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO LEU THR SEQRES 4 A 286 LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS THR THR SEQRES 5 A 286 ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SER LEU SEQRES 6 A 286 MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS ILE THR SEQRES 7 A 286 PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE ARG ILE SEQRES 8 A 286 PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA VAL GLN SEQRES 9 A 286 GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY PHE VAL SEQRES 10 A 286 ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU LYS TYR SEQRES 11 A 286 GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SER LEU SEQRES 12 A 286 MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY GLN GLY SEQRES 13 A 286 PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG LYS PRO SEQRES 14 A 286 PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE ALA VAL SEQRES 15 A 286 LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP LEU ALA SEQRES 16 A 286 ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP ARG PRO SEQRES 17 A 286 GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE GLN ASP SEQRES 18 A 286 ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS LEU ASN SEQRES 19 A 286 HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU LEU GLN SEQRES 20 A 286 LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU HIS VAL SEQRES 21 A 286 GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR ASP MET SEQRES 22 A 286 SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS ASP LEU SEQRES 1 B 286 GLY SER HIS MET ALA GLU ILE SER SER ASP ILE ASP GLN SEQRES 2 B 286 LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU ALA LYS SEQRES 3 B 286 HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO LEU THR SEQRES 4 B 286 LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS THR THR SEQRES 5 B 286 ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SER LEU SEQRES 6 B 286 MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS ILE THR SEQRES 7 B 286 PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE ARG ILE SEQRES 8 B 286 PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA VAL GLN SEQRES 9 B 286 GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY PHE VAL SEQRES 10 B 286 ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU LYS TYR SEQRES 11 B 286 GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SER LEU SEQRES 12 B 286 MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY GLN GLY SEQRES 13 B 286 PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG LYS PRO SEQRES 14 B 286 PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE ALA VAL SEQRES 15 B 286 LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP LEU ALA SEQRES 16 B 286 ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP ARG PRO SEQRES 17 B 286 GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE GLN ASP SEQRES 18 B 286 ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS LEU ASN SEQRES 19 B 286 HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU LEU GLN SEQRES 20 B 286 LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU HIS VAL SEQRES 21 B 286 GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR ASP MET SEQRES 22 B 286 SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS ASP LEU
HET DKD A 1 26
HETNAM DKD (2S)-2-(4-PHENETHYLPHENOXY)-3-PHENYL-PROPANOIC ACID
FORMUL 3 DKD C23 H22 O3 FORMUL 4 HOH *106(H2 O)
HELIX 1 1 GLU A 207 PHE A 226 1 20 HELIX 2 2 THR A 229 THR A 238 1 10 HELIX 3 3 THR A 241 SER A 245 5 5 HELIX 4 4 ASP A 251 ILE A 262 1 12 HELIX 5 5 GLU A 276 SER A 302 1 27 HELIX 6 6 GLY A 305 LEU A 309 5 5 HELIX 7 7 ASP A 310 ALA A 331 1 22 HELIX 8 8 SER A 342 GLY A 344 5 3 HELIX 9 9 ARG A 350 SER A 355 1 6 HELIX 10 10 PRO A 359 PHE A 363 5 5 HELIX 11 11 MET A 364 ASN A 375 1 12 HELIX 12 12 ALA A 376 GLU A 378 5 3 HELIX 13 13 ASP A 380 LEU A 393 1 14 HELIX 14 14 VAL A 403 HIS A 425 1 23 HELIX 15 15 GLN A 430 GLU A 460 1 31 HELIX 16 16 HIS A 466 TYR A 473 1 8 HELIX 17 17 GLU B 207 PHE B 226 1 20 HELIX 18 18 THR B 229 LEU B 237 1 9 HELIX 19 19 ASP B 251 MET B 257 1 7 HELIX 20 20 GLU B 276 LYS B 301 1 26 HELIX 21 21 GLY B 305 LEU B 309 5 5 HELIX 22 22 ASP B 310 ALA B 331 1 22 HELIX 23 23 SER B 342 GLY B 344 5 3 HELIX 24 24 ARG B 350 SER B 355 1 6 HELIX 25 25 ARG B 357 ASP B 362 1 6 HELIX 26 26 MET B 364 ALA B 376 1 13 HELIX 27 27 ASP B 380 LEU B 393 1 14 HELIX 28 28 ASN B 402 HIS B 425 1 24 HELIX 29 29 GLN B 430 LYS B 457 1 28 HELIX 30 30 HIS B 466 ILE B 472 1 7
SHEET 1 A 4 PHE A 247 ILE A 249 0 SHEET 2 A 4 GLY A 346 THR A 349 1 O PHE A 347 N ILE A 249 SHEET 3 A 4 GLY A 338 ILE A 341 -1 N VAL A 339 O MET A 348 SHEET 4 A 4 MET A 334 ASN A 335 -1 N ASN A 335 O GLY A 338 SHEET 1 B 4 PHE B 247 ILE B 249 0 SHEET 2 B 4 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 B 4 GLY B 338 ILE B 341 -1 N ILE B 341 O GLY B 346 SHEET 4 B 4 MET B 334 ASN B 335 -1 N ASN B 335 O GLY B 338
SITE 1 AC1 13 ILE A 279 PHE A 282 GLN A 283 CYS A 285 SITE 2 AC1 13 GLN A 286 SER A 289 HIS A 323 ILE A 326 SITE 3 AC1 13 HIS A 449 LEU A 453 MET A 463 LEU A 469 SITE 4 AC1 13 TYR A 473
CRYST1 93.790 61.459 121.100 90.00 102.49 90.00 C 1 2 1 8
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.010662 0.000000 0.002362 0.00000
SCALE2 0.000000 0.016271 0.000000 0.00000
SCALE3 0.000000 0.000000 0.008458 0.00000